The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.
Down 99%, biotech firm 180 Life Sciences pivots to crypto with ETH bet
Related Posts
US lawmakers raise concerns over Apple’s crypto and NFT policies
Two U.S. lawmakers have written to Apple CEO Tim Cook, raising concern about how the company’s guidelines may…
Pepe, Doge veterans are racing into this new memecoin: XYZVerse eyes 6,500%+ upside
After Pepe and Dogecoin, investors are eyeing XYZVerse for its 6,500% return potential in the memecoin space. #partnercontent
Ethereum developer details technical barriers to reversing $1.4b Bybit hack
An Ethereum developer provided an explanation of why the network cannot “rollback” transactions to recover Bybit’s stolen $1.4…
